Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Biogen IncBIIB12.852.161.278.8510.47%5.02%59.96$148.11$194.6470,051$142.35

Detail of Biogen Inc

 
CEO
Mr. Christopher A. Viehbacher
Employees
7570
Industry
Drug Manufacturers - General
Sector
Healthcare
Market cap
$21B

Company details

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$9.61B
Cost of goods (CoG)
-$2.35B
Gross profit (GP)
$7.26B
Operating expense (OE)
-$4.66B
Research and development (R&D)
-$2.08B
General and administrative (G&A)
-$2.33B
Other (OTH)
-$251.60M
Operating income (OI)
$2.23B
Other income expense (OIE)
-$131.00M
Pretax income (PI)
$1.91B
Tax (TAX)
-$291.70M
Net income (NI)
$1.61B
Biogen Inc
BIIB • XNGS • US
$142.35
-98.17 (-40.81%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$11.08
Margin profit
16.81%
52 week low
$140.130005
52 week high
$244.740005
50-day simple moving average
$145.31
200-day simple moving average
$148.11
Percent held by insiders
0.15%
Percent held by institutions
95.22%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
BIIB -40.75%
eps change
BIIB 0.00%